^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TrkA receptor antagonist

    Related drugs:
    23d
    Taletrectinib as an emerging therapy for ROS1-positive non-small cell lung cancer: findings from TRUST phase 2 trials. (PubMed, Ann Med Surg (Lond))
    In ROS1-positive NSCLC patients, taletrectinib has been effective and well tolerated, as evidenced by early clinical trials, including those that are resistant to crizotinib. It demonstrates potential for disease control, as it has excellent oral absorption and is able to combat the spread of neurological disorders. Taletrectinib is emerging as a promising candidate for enhancing the outcomes of patients with ROS1-positive lung cancer as the treatment landscape for this disease continues to evolve.
    P2 data • Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 positive
    |
    Xalkori (crizotinib) • Ibtrozi (taletrectinib)
    29d
    TRUST-I: A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (clinicaltrials.gov)
    P2, N=173, Active, not recruiting, Nuvation Bio Inc. | Trial completion date: Dec 2025 --> Jun 2027
    Trial completion date
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Ibtrozi (taletrectinib)
    1m
    AB-106-C205: Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion (clinicaltrials.gov)
    P2, N=14, Terminated, Nuvation Bio Inc. | N=40 --> 14 | Recruiting --> Terminated; The study was discontinued early by the Sponsor for business reasons on 06 Dec 2024
    Enrollment change • Trial termination • Pan tumor
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    Ibtrozi (taletrectinib)
    3ms
    VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    Keytruda (pembrolizumab) • VMD-928
    4ms
    Targeting ROS1 in NSCLC: Clinical Advances and Future Directions of Taletrectinib. (PubMed, Zhongguo Ying Yong Sheng Li Xue Za Zhi)
    Findings show that taletrectinib has a promising anticancer impact, good CNS penetration, and a solid safety record, especially in patients with brain metastases. These results imply that ROS1-positive cancers may benefit from taletrectinib as a treatment.
    Review • Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 positive
    |
    Ibtrozi (taletrectinib)
    5ms
    TRUST-II: Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (clinicaltrials.gov)
    P2, N=217, Active, not recruiting, Nuvation Bio Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2027 --> Dec 2027
    Enrollment closed • Trial completion date
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Ibtrozi (taletrectinib)
    5ms
    Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New trial • Real-world evidence
    |
    Rozlytrek (entrectinib) • Ibtrozi (taletrectinib)
    6ms
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) (clinicaltrials.gov)
    P3, N=180, Recruiting, Nuvation Bio Inc.
    New P3 trial
    |
    Ibtrozi (taletrectinib)